Immune checkpoint blockers (ICBs) targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have shown promise in specific STS histotypes [22–24], but are ineffective for most patients [25, 26]. Here, PDCD1 is linked to telomere syndrome.